IN2PHARMA
ActiveSummary
IN2PHARMA has been active since 2008 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €69,300 and a net result of €909,969. Equity remains stable across the filed financial years (±0% per year). Its solvency ranks better than 11% of 3,821 sector peers (NACE 70, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Group and network
Holdings and subsidiaries
2 holdingsHoldings 2
- KDT CONSULTING, AFGEKORT : KDTsubsidiarySourceact 11-05-2026100%
- STUDIO PHARMAsubsidiary100%
Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Connections & network
3 current directorsThe board mandates are listed below; here you explore them as a network.